ORKA financial statements
The full income statement, balance sheet, and cash-flow statement for Oruka Therapeutics Inc. (ORKA), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | — | — | 0.00 | 0.00 | 0.00 | |
| 122M+38.5% | 88.1M+1107.8% | 7.30M-31.1% | 10.6M-45.2% | 19.3M+98.0% | ||
| Research & development | 101M+34.1% | 75.1M+7309.7% | 1.01M-78.7% | 4.75M-65.7% | 13.8M+177.1% | |
| Selling, general & administrative | 21.4M+63.9% | 13.1M+107.9% | 6.28M+7.5% | 5.85M+6.3% | 5.50M+15.3% | |
| General & administrative | 21.4M+63.9% | 13.1M+107.9% | 6.28M+7.5% | 5.85M+6.3% | 5.50M+15.3% | |
| Operating income | -122M-38.5% | -88.1M-1107.8% | -7.30M+31.1% | -10.6M+45.2% | -19.3M-98.0% | |
| Interest expense | — | 1.47M | — | — | — | |
| Interest & investment income | 16.6M+183.6% | 5.86M | — | — | — | |
| Other non-operating income | 16.6M+415350.0% | 4.00K | — | — | — | |
| Pre-tax income | -105M | — | — | — | -19.3M-98.2% | |
| Income tax | — | — | 0.00 | 0.00 | 0.00+100.0% | |
| Net income | -105M-25.9% | -83.7M-1468.2% | -5.34M+46.2% | -9.93M+48.6% | -19.3M-98.4% | |
| — | — | -$0.37+46.4% | -$0.69+50.4% | -$1.39 | ||
| EPS (basic) | — | — | -$0.37+46.4% | -$0.69+50.4% | -$1.39 | |
| Weighted-avg shares (basic) | — | 16.8M+16.5% | 14.4M+0.0% | 14.4M+3.6% | 13.9M | |
| Weighted-avg shares (diluted) | — | 16.8M+16.5% | 14.4M+0.0% | 14.4M+3.6% | 13.9M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 344M-8.8% | 377M+902.5% | 37.6M-12.0% | 42.7M-21.5% | 54.4M+8.9% | ||
| Cash & equivalents | 46.9M-23.8% | 61.6M+64.5% | 37.4M-11.8% | 42.4M-20.5% | 53.4M+8.7% | |
| Short-term investments | 290M-7.6% | 314M | — | — | — | |
| Prepaid expenses | 6.81M+458.0% | 1.22M | — | — | — | |
| Other current assets | — | — | 161K-36.6% | 254K-76.1% | 1.06M+18.4% | |
| 489M+23.4% | 396M+946.0% | 37.9M-12.1% | 43.1M-21.6% | 54.9M+8.9% | ||
| Property, plant & equipment | 288K+77.8% | 162K+1520.0% | 10.0K-60.0% | 25.0K-47.9% | 48.0K+128.6% | |
| Operating lease right-of-use | 1.83M+108.9% | 876K+254.7% | 247K-28.0% | 343K-21.5% | 437K+2.1% | |
| Long-term investments | 143M+688.9% | 18.1M | — | — | — | |
| Other non-current assets | 103K+139.5% | 43.0K+258.3% | 12.0K-33.3% | 18.0K+0.0% | 18.0K+50.0% | |
| 15.4M+17.9% | 13.0M+1947.6% | 637K-43.7% | 1.13M-67.6% | 3.50M-0.0% | ||
| Accounts payable | 4.16M+20.0% | 3.46M+856.4% | 362K+8.4% | 334K-70.1% | 1.12M-37.0% | |
| Current lease liability | 619K+190.6% | 213K+180.3% | 76.0K-26.2% | 103K+3.0% | 100K+143.9% | |
| 16.7M+20.9% | 13.8M+1540.7% | 841K-40.4% | 1.41M-63.6% | 3.88M-0.7% | ||
| Non-current lease liability | 1.31M+73.9% | 755K+270.1% | 204K-27.1% | 280K-26.9% | 383K-6.4% | |
| Operating lease liability (total) | 1.93M+99.6% | 968K+245.7% | 280K-26.9% | 383K-20.7% | 483K+7.3% | |
| 472M+23.5% | 382M+932.5% | 37.0M-11.2% | 41.7M-18.4% | 51.0M+9.7% | ||
| Common stock | 49.0K+32.4% | 37.0K+164.3% | 14.0K+0.0% | 14.0K+0.0% | 14.0K+40.0% | |
| Additional paid-in capital | 658M+42.0% | 463M+105.1% | 226M+0.3% | 225M+0.2% | 225M+11.9% | |
| Retained earnings | -189M-125.9% | -83.7M+55.6% | -189M-2.9% | -183M-5.7% | -173M-12.5% | |
| Accumulated other comprehensive income | 546K+1431.7% | -41.0K | — | — | — | |
| Total liabilities & equity | 489M+23.4% | 396M+946.0% | 37.9M-12.1% | 43.1M-21.6% | 54.9M+8.9% | |
| Common shares issued | 48.7M+30.1% | 37.4M+158.2% | 14.5M+0.6% | 14.4M+0.0% | 14.4M+50.9% | |
| Common shares outstanding | 48.7M+30.1% | 37.4M+158.2% | 14.5M+0.6% | 14.4M+0.0% | 14.4M+50.9% | |
| Shares outstanding (cover) | 49.5M+32.3% | 37.4M+158.2% | 14.5M+0.6% | 14.4M+0.0% | 14.4M+0.0% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -88.2M-52.5% | -57.8M-1053.5% | -5.01M+54.1% | -10.9M+41.8% | -18.8M-142.9% | ||
| Depreciation & amortization | 83.0K+207.4% | 27.0K+80.0% | 15.0K-25.0% | 20.0K+25.0% | 16.0K+100.0% | |
| Share-based compensation | 24.2M+62.5% | 14.9M+2074.8% | 686K+23.4% | 556K+11.9% | 497K+1055.8% | |
| Change in payables | — | — | 28.0K+103.6% | -783K-90.5% | -411K-137.3% | |
| -96.7M+70.7% | -330M | 0.00+100.0% | -2.00K+95.3% | -43.0K-126.3% | ||
| Capital expenditure | 209K+10.6% | 189K | 0.00-100.0% | 2.00K-95.3% | 43.0K+126.3% | |
| Free cash flow | -88.4M-52.4% | -58.0M-1057.3% | -5.01M+54.1% | -10.9M+42.0% | -18.8M-142.8% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 170M-62.1% | 450M | 0.00 | 0.00-100.0% | 23.1M-52.3% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 671K+1142.6% | 54.0K | 0.00 | 0.00-100.0% | 24.1M-52.7% | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other financing activities | — | 228M | — | — | — | |
| Net change in cash | — | — | -5.01M+54.1% | -10.9M-354.5% | 4.29M-89.5% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.50B+106.8% | 726M+147.0% | 294M-28.3% | 410M+10.2% | 372M-46.4% | |
| P/B | 3.2×+67.5% | 1.9×-75.5% | 7.7×-19.3% | 9.6×+31.7% | 7.3×-51.1% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: ORKA’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ORKA filings on SEC EDGAR → Not investment advice.